CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications.

Azevedo, Rita; Gaiteiro, Cristiana; Peixoto, Andreia; Relvas-Santos, Marta; Lima, Luís; Santos, Lúcio Lara; Ferreira, José Alexandre

Azevedo, Rita; Gaiteiro, Cristiana; Peixoto, Andreia; Relvas-Santos, Marta; Lima, Luís; Santos, Lúcio Lara; Ferreira, José Alexandre.

Afiliación

Azevedo R; 1Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Gaiteiro C; 2Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.
Peixoto A; 1Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Relvas-Santos M; 2Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.
Lima L; 3Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Santos LL; 1Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Ferreira JA; 2Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.

Clin Proteomics ; 15: 22, 2018.

Article en En | MEDLINE | ID: mdl-29983670

Palabras clave

CD44; CD44 isoforms; Cancer biomarkers; Glycosylation; Nomenclature

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Proteomics Año: 2018 Tipo del documento: Article País de afiliación: Portugal

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google